Literature DB >> 22042953

Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?

Stephen J Schuster, Sattva S Neelapu, Carlos F Santos, Mihaela A Popa-McKiver, Amy M McCord, Larry W Kwak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22042953      PMCID： PMC3255991          DOI： 10.1200/JCO.2011.38.6094

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

Authors:  Stephen J Schuster; Sattva S Neelapu; Barry L Gause; John E Janik; Franco M Muggia; Jon P Gockerman; Jane N Winter; Christopher R Flowers; Daniel A Nikcevich; Eduardo M Sotomayor; Dean S McGaughey; Elaine S Jaffe; Elise A Chong; Craig W Reynolds; Donald A Berry; Carlos F Santos; Mihaela A Popa; Amy M McCord; Larry W Kwak
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

2.  Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.

Authors:  Stephen M Ansell; Vera J Suman
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

3.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321
  3 in total
  2 in total

Review 1.  Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.

Authors:  Elena Muraro; Debora Martorelli; Riccardo Dolcetti
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

2.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.